Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
June 04, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
May 28, 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
May 14, 2024 10:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 08, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
March 14, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
March 05, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
January 29, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
January 09, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...